ClinicalTrials.gg
Active, not recruitingNCT07535606Updated Nov 12, 2026

A Study to Evaluate ALN-4915 in Adult Healthy Volunteers

A Phase 1 interventional study of ALN-4915 and Placebo in Healthy Volunteers, sponsored by Alnylam Pharmaceuticals. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Alnylam Pharmaceuticals · Phase 1, Interventional, and Treatment

Updated Oct 15, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • siRNA
  • RNAi
03

In context

Lead sponsor

Alnylam Pharmaceuticals is the lead sponsor of 84 studies on the registry; 18 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is willing and able to complete all study assessments

Exclusion criteria

Exclusion Criteria:

  • Has (ALT) or aspartate aminotransferase (AST) > (ULN)
  • Has total >ULN
  • Has no history of invasive infection by an encapsulated organism
  • Has no known complement or immunologic deficiency
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    ALN-4915

    Participants will be administered a single dose of ALN-4195.

    Drug: ALN-4915

  • Placebo comparator
    Placebo

    Participants will be administered a single dose of placebo.

    Drug: Placebo

Interventions

  • DrugALN-4915

    ALN-4915 will be administered subcutaneously (SC)

  • DrugPlacebo

    Placebo will be administered SC

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events

    Time frame: Serious adverse events (SAEs) after signing of ICF up to Month 12; nonserious AEs after first dose of study drug up to Month 12

Secondary outcomes

  1. Change from Baseline Inflammatory Markers in Plasma

    Time frame: Baseline up to Month 9

  2. Concentration of ALN-4915 in Plasma

    Time frame: Predose up to Day 3

  3. Concentration of ALN-4915 in Urine

    Time frame: Predose up to Day 1

07

Study locations

1 site
  • Clinical Trial Site
    London, NW10 7EW, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jul 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Apr 17, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 15, 2026
Enrollment
44 (estimated)→36 (actual)
Oct 15, 2026
Show all 2 updates
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 15, 2026
    Recruiting→Active, not recruiting
    Enrollment 44 (estimated)→36 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07535606
Responsible party
Sponsor
First posted
Apr 17, 2026
Start date
Mar 2, 2026
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion